MA39110A1 - Nouveau composé pour le traitement de l'hypoglycémie grave - Google Patents

Nouveau composé pour le traitement de l'hypoglycémie grave

Info

Publication number
MA39110A1
MA39110A1 MA39110A MA39110A MA39110A1 MA 39110 A1 MA39110 A1 MA 39110A1 MA 39110 A MA39110 A MA 39110A MA 39110 A MA39110 A MA 39110A MA 39110 A1 MA39110 A1 MA 39110A1
Authority
MA
Morocco
Prior art keywords
treatment
new compound
severe hypoglycemia
hypoglycemia
severe
Prior art date
Application number
MA39110A
Other languages
English (en)
Other versions
MA39110B1 (fr
Inventor
Jorge Alsina-Fernandez
Robert Chadwick Cummins
Lili Guo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52273565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39110(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39110A1 publication Critical patent/MA39110A1/fr
Publication of MA39110B1 publication Critical patent/MA39110B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne un nouveau composé utile dans le traitement de l'hypoglycémie.
MA39110A 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie grave MA39110B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917716P 2013-12-18 2013-12-18
PCT/US2014/069644 WO2015094876A1 (fr) 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie grave

Publications (2)

Publication Number Publication Date
MA39110A1 true MA39110A1 (fr) 2017-09-29
MA39110B1 MA39110B1 (fr) 2018-04-30

Family

ID=52273565

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39110A MA39110B1 (fr) 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie grave

Country Status (22)

Country Link
US (1) US20160311882A1 (fr)
EP (1) EP3083667A1 (fr)
KR (1) KR20160075826A (fr)
CN (1) CN105829340A (fr)
AP (1) AP2016009267A0 (fr)
AR (1) AR098615A1 (fr)
AU (1) AU2014366425B2 (fr)
BR (1) BR112016010635A2 (fr)
CA (1) CA2930596A1 (fr)
CR (1) CR20160227A (fr)
DO (1) DOP2016000142A (fr)
EA (1) EA201690966A1 (fr)
HK (1) HK1224305A1 (fr)
IL (1) IL245491A0 (fr)
MA (1) MA39110B1 (fr)
MX (1) MX2016007988A (fr)
PE (1) PE20160847A1 (fr)
PH (1) PH12016501183A1 (fr)
SG (1) SG11201604237PA (fr)
TN (1) TN2016000208A1 (fr)
TW (1) TW201609128A (fr)
WO (1) WO2015094876A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (fr) 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
WO2020163125A1 (fr) 2019-02-05 2020-08-13 Eli Lilly And Company Agonistes analogiques du glucagon et leurs procédés d'utilisation
EP3947451A1 (fr) 2019-04-01 2022-02-09 Novo Nordisk A/S Anticorps dirigés contre le liraglutide et leur utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
WO2009099763A1 (fr) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d’esters
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP3434687B1 (fr) * 2011-06-10 2021-03-10 Hanmi Science Co., Ltd. Dérivés inédits d'oxyntomoduline et composition pharmaceutique destinée au traitement de l'obésité en contenant
EP2729493B1 (fr) * 2011-07-04 2020-06-10 IP2IPO Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire

Also Published As

Publication number Publication date
AU2014366425B2 (en) 2016-12-08
PE20160847A1 (es) 2016-09-10
IL245491A0 (en) 2016-06-30
MX2016007988A (es) 2016-09-09
PH12016501183A1 (en) 2016-07-25
AR098615A1 (es) 2016-06-01
HK1224305A1 (zh) 2017-08-18
AU2014366425A1 (en) 2016-05-26
WO2015094876A1 (fr) 2015-06-25
EP3083667A1 (fr) 2016-10-26
AP2016009267A0 (en) 2016-06-30
CR20160227A (es) 2016-07-12
MA39110B1 (fr) 2018-04-30
EA201690966A1 (ru) 2016-12-30
US20160311882A1 (en) 2016-10-27
DOP2016000142A (es) 2016-07-15
TN2016000208A1 (en) 2017-10-06
BR112016010635A2 (pt) 2017-12-05
CN105829340A (zh) 2016-08-03
TW201609128A (zh) 2016-03-16
KR20160075826A (ko) 2016-06-29
CA2930596A1 (fr) 2015-06-25
SG11201604237PA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
MA37740A1 (fr) Seringue
EA201591491A1 (ru) Соединения тетрагидропирролотиазина
EA201491391A1 (ru) Терапевтически активные соединения и способы их применения
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
AR095097A1 (es) Compuestos de fenoxietoxi
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
CO7141429A2 (es) Nuevos compuestos de pirazol
MA39110A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
EA201690763A1 (ru) Лечение рака поджелудочной железы
MA42166A1 (fr) Seringue
MA39109A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39108A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie sévère
EA201690214A1 (ru) Способ лечения гипертрофической кардиомиопатии
MA39432A (fr) Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside
EA201690593A1 (ru) Новые соединения мочевины
UA113753C2 (xx) Фенілзаміщені кетоеноли для боротьби з паразитами риб
MA38931A1 (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
EA201600013A1 (ru) Основание ковша и ковш
MA38411B1 (fr) Inhibiteurs de cdc7